Les news de phylogene

News

Microbiome et cancer

If you missed out our October Awareness month posts on Linked In, now the time to catch-up! Post were addressing the role of microbiota in cancers, from his emerging role in Tumor Microenvironment to his singularity in Breast Cancer tissue.

Phylogene is proud to participate in raising awareness of breast cancer during Breast Cancer Awareness Month!

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

The tumor microenvironment (TME) is a complex ecosystem, which includes many different types of cells, abnormal vascular systems, and immunosuppressive cytokines. TME serves an important function in tumor tolerance and escapes from immune surveillance leading to tumor progression (1).

In few words:

  • Gut microbiota can shape TME by regulating the immune and hormonal factors of the whole host, in other words, host gut microbiota is emerging as a critical modulator of the TME.
  • An in-depth understanding of TME, its role and related molecules will provide important insights into the biological behavior of different tumor types.

 

The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View

Excellent review asking pragmatic questions regarding the role of microbiome in cancers and the need to use multiomic approaches for better data integration (2).

“Outstanding Questions”:

  • What other members of the human microbiome beyond bacteria –archaea, fungi, and viruses (including bacteriophages) – are important for cancer?
  • How can we integrate microbial composition and function with other relevant data such as habitat, host information, and other variables quantified by omic approaches?
  • Does the human microbiome play a role in the link between migration and cancer incidence?
  • Why does the success of microbiota transplants vary from patient to patient?
  • Can the ability of gut microbes to influence the central nervous system be leveraged to manage pain in cancer patients or even cancer development?
  • Can we engineer microbiomes to turn immunotherapy nonresponders into responders?

 

Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response

The human microbiome is a mysterious treasure of the body playing endless important roles in the host’s metabolism, digestion, immunity and well-being. On the other hand, it actively participates in the development of a variety of pathological conditions including Cancer (3).

This review highlights few interesting findings regarding microbiota in breast cancer:

  • Breast cancer tissue contains its own unique microbiota
  • Preclinical data indicates that breast microbiota dysbiosis contributes to breast cancer initiation and progression
  • Differences in breast microbiota composition have been found between breast cancer subtypes and disease severities that may contribute to immunosuppression
  • Interactions between breast microbiota, gut microbiota, and immune system (Breast – Gut Axis)

 

Microbiome and Breast Cancer: New Role for an Ancient Population

The human microbiome is a mysterious treasure of the body playing endless important roles in the host’s metabolism, digestion, immunity and well-being. Although the multiple evidences liking the microbiome to Breast Cancer (BC) are undeniable, there are essential questions to be answered to unlock the exact role of the microbiome in the development and treatment of BC (4).

This review aimed at evaluating:

  • The role of the microbiome as a risk factor in the occurrence of BC investigating and assessing the impact of the altered composition of breast, guts, and milk microbiome in the physiological status of normal breast as well as cancerous or non-cancerous breast lesions.
  • The role of microbiome in the development and maintenance of inflammation
  • Clinical and therapeutic applications of the microbiome- e.g., probiotics, microbiome            genome modulation, and engineered microbiome enzymes in the management of BC

What is the role of microbiota in cancers? Protectant or enhancer of the disease?

With Phylogene you can characterize bacterial populations in Tumor microenvironment and elucidate metabolic pathways. Just think out of the box!

  • Bacterial 16s rDNA and fungal ITS sequencing with OUT-based estimation to investigate microbial diversity and determine taxonomic composition.
  • High-resolution nano LC-MS/MS quantitative metaproteomics and HolXplore™ data processing, for host-microbiota interactions discovery.

 

(1).https://www.frontiersin.org/articles/10.3389/fimmu.2020.612202/full

(2).https://www.cell.com/trends/cancer/fulltext/S2405-8033(20)30017-0

(3).https://doi.org/10.1016/j.ajpath.2021.02.020

(4).https://www.frontiersin.org/articles/10.3389/fonc.2020.00120/full

 

PHYLOGENE

62, Route Nationale 113

30620 BERNIS

Tel : +33 4 66 04 77 99 Fax : +33 4 66 04 77 97

e-mail : r.arnaud@phylogene.com

web : www.phylogene.com

 

For our latest News, articles and activities please follow us on LinkedIn!

Lire +

News

Publication dans Int J of Cosmetic Science

Une nouvelle publication qui montre comment la protéomique LC-MS/MS peut révéler en non-ciblé les modifications du protéome du collagène intracellulaire des fibroblastes induites par différents traitements

Lire +

News

Tout savoir sur la préparation des échantillons protéiques en dermo-cosmétique

Découvrez les dernières évolutions pour la préparation des échantillons protéiques en dermo-cosmétique chez Phylogene. Jean-Marc Monneuse, notre spécialiste en LC-MS/MS nous présentera les dernières évolutions en protéomique haute résolution pour l'extraction des strips.

Lire +

News

Focus de Skinobs sur l'objectivation des soins capillaires

Notre article sur la caractérisation du métabolisme du microbiote sur le scalp

Lire +

News

PUBLICATION dans COSMETICOBS

Notre article dans Cosmeticobs sur les modes d'action sur la peau et son microbiote par les techniques omiques

Lire +

News

BIO Digital 2021

PHYLOGENE participe à BIO Digital les 10-11 & 14-18 Juin, 2021 et au One-on-One Partnering.
Nous serions ravis de parler de vos projets et de ce que nous pourrions faire pour vous.

Lire +

News

LANCEMENT DE L'ALLIANCE PROMOTION MICROBIOTE

PHYLOGENE rejoint l'Alliance pour la Promotion du Microbiote

Cette initiative rassemble les principaux acteurs de l'industrie du microbiome dans des efforts pour placer le microbiome au c½ur des stratégies diagnostiques et thérapeutiques pour une meilleures santé.

Lire +

News

NOS EVENEMENTS

Merci pour le temps passé avec nous à BIOFIT 2020,Oncology virtual partnering meeting 2021, NUTREVENT 2021 rendez-vous à la prochaine édition.

 

Lire +

News

PUBLICATION EN HEMATOLOGIE

Une publication en hématologie basée sur échantillons de plasma analysés en protéomique haute résolution, nanoLC-MS/MS, méthode de choix pour générer des biomarqueurs

Lire +

CRO en omique et bioinformatique associée dont discovery en pharma et cosmétique ou détection des allergènes en agroalimentaire

Phylogene, créée en 1999, est une société de services en biotechnologie utilisant les techniques de génomique, transcriptomique, protéomique, métabolomique et bioinformatique associée pour des applications d’identification et d’authentification ou pour mettre en évidence des effets biologiques.

Aujourd'hui, les applications sont essentiellement le service pour la santé dont le diagnostic, la cosmétique, l'environnement, sous forme d’analyse ou d’expertise, et à l’industrie du diagnostic, comme développeur de kits et à la filière agroalimentaire dont la détection des allergènes, la microbiologie, l'identification d'espèces et les OGMs.

Bonne visite !

Accréditation COFRAC n°1-2128-essais- portée disponible sur www.cofrac.fr

 

Références

Ils nous ont fait confiance